These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22423020)

  • 21. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy.
    Bukowinski AT; Hall C; Chang RN; Gumbs GR; Marie S Conlin A
    Vaccine; 2020 Aug; 38(37):5933-5939. PubMed ID: 32712082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers.
    Sharma R; Sharma CL
    J Cancer Res Ther; 2007; 3(2):92-5. PubMed ID: 17998730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT; Castellsagué X; Garland SM
    Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quadrivalent HPV vaccination reactions--more hype than harm.
    Douglas RJ
    Aust Fam Physician; 2009 Mar; 38(3):139-42. PubMed ID: 19283255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
    Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
    Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
    Geier DA; Geier MR
    Immunol Res; 2017 Feb; 65(1):46-54. PubMed ID: 27406735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
    Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cervical cancers after human papillomavirus vaccination.
    Beller U; Abu-Rustum NR
    Obstet Gynecol; 2009 Feb; 113(2 Pt 2):550-552. PubMed ID: 19155953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse events and quadrivalent human papillomavirus recombinant vaccine.
    Debold V; Hurwitz E
    JAMA; 2009 Dec; 302(24):2657; author reply 2657-8. PubMed ID: 20040547
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of quadrivalent human papillomavirus vaccine.
    Omer SB
    J Intern Med; 2012 Feb; 271(2):177-8. PubMed ID: 22077556
    [No Abstract]   [Full Text] [Related]  

  • 34. Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes.
    Scheller NM; Pasternak B; Mølgaard-Nielsen D; Svanström H; Hviid A
    N Engl J Med; 2017 Mar; 376(13):1223-1233. PubMed ID: 28355499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus.
    Mavundza EJ; Wiyeh AB; Mahasha PW; Halle-Ekane G; Wiysonge CS
    Hum Vaccin Immunother; 2020; 16(2):426-435. PubMed ID: 31448991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing human papillomavirus vaccine efficacy and safety.
    Hendrix SL
    J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy.
    Lipkind HS; Vazquez-Benitez G; Nordin JD; Romitti PA; Naleway AL; Klein NP; Hechter RC; Jackson ML; Hambidge SJ; Lee GM; Sukumaran L; Kharbanda EO
    Obstet Gynecol; 2017 Sep; 130(3):599-608. PubMed ID: 28796684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects.
    Kang S; Kim KH; Kim YT; Kim YT; Kim JH; Song YS; Shin SH; Ryu HS; Han JW; Kang JH; Park SY
    Int J Gynecol Cancer; 2008; 18(5):1013-9. PubMed ID: 17986242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
    Yancey AM; Pitlick JM; Forinash AB
    Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.